Rossari Biotech Ossari Biotech Ltd (NSE: ROSSARI, BSE: 543213) is a Mumbai, Maharashtra-based company in the Specialty Formulations industry. With a market capitalisation of ₹2,380 Cr, it ranks #1,160 by market cap among the 6,197 Indian listed companies on FinBizNet. At ₹435.10 (as of 16 Nov 2026), the share price is 31.9% below its 52-week high of ₹638.70 and 16.0% above its 52-week low of ₹375.00. The share price is down 30.5% over one year and down 12.3% over three months.
| Current Price | ₹435.10 |
|---|---|
| Market Cap | ₹2,380 Cr |
| NSE Symbol | ROSSARI |
| BSE Code | 543213 |
| Sector | Materials > Chemicals > Speciality Chemicals |
| Sub-Industry | Specialty Chemicals > Specialty Formulations |
| P/E Ratio | 16 |
| Return on Equity | 11.85% |
| Return on Assets | 5.67% |
| 52-Week Range | ₹375.00 – ₹638.70 |
| 1-Year Price Change | -30.5% |
| 3-Month Price Change | -12.3% |
| Beta (1Y) | 0.7 |
| Dividend Yield | 0.12% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.rossari.com |
| Revenue | ₹698 Cr |
|---|---|
| Net Profit | ₹39 Cr |
| Net Margin | 5.6% |
| EPS (Basic) | ₹7.02 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Rossari Biotech Ossari Biotech Ltd reported revenue of ₹698 Cr in Q2 FY27, up 19.0% from ₹586 Cr in Q2 FY26 and up 0.1% from ₹697 Cr in Q1 FY27. It posted a net profit of ₹39 Cr for the quarter, against a net profit of ₹37 Cr in Q2 FY26 (up 5.5%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹544 Cr (Q1 FY26) to ₹698 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹698 Cr | ₹39 Cr | 5.6% |
| Q1 FY27 | ₹697 Cr | ₹35 Cr | 5.0% |
| Q4 FY26 | ₹685 Cr | ₹46 Cr | 6.7% |
| Q3 FY26 | ₹582 Cr | ₹33 Cr | 5.6% |
| Q2 FY26 | ₹586 Cr | ₹37 Cr | 6.3% |
| Q1 FY26 | ₹544 Cr | ₹34 Cr | 6.2% |
| Q4 FY25 | ₹580 Cr | ₹34 Cr | 5.9% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 68.14% of Rossari Biotech Ossari Biotech Ltd's shares as of Sept 2026, against 68.17% in Sept 2025 (−0.03 percentage points). Delivery averaged 55.9% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Rossari Biotech Limited manufactures and sells specialty chemicals in India and internationally. It offers soap and detergents; inks, paints, and coatings; ceramics and tiles; pulp and papers; cement; performance additives; and water treatment solutions. The company also provides textile specialty chemicals, such as cotton, polyester, acrylic, wool, silk, nylon, functional finishes, denim, printing, and sustainable solutions; and pet grooming products, which include natural pet shampoos, powders, deodorants, sprays, creams, and floor washing liquids under the Lozalo, Hunger Fills, and Sniffy brand names. In addition, it offers poultry nutrition products comprising vitamin-mineral formulations, toxin binders, individual and cocktail enzymes, liquid nutraceuticals, and supplements or herbal preparations. The company was formerly known as Rossari Labtech and changed its name to Rossari Biotech Limited in December 2003. Rossari Biotech Limited was founded in 1997 and is based in Mumbai, In
1. Speciality Chemicals-This segment manufactures and sells specialty chemicals.
1. Speciality Chemicals-100%
Rossari Biotech Ossari Biotech Ltd is trading at ₹435.10, with a market capitalisation of ₹2,380 Cr.
Rossari Biotech Ossari Biotech Ltd operates in the Materials > Chemicals > Speciality Chemicals space (Specialty Chemicals > Specialty Formulations).
Rossari Biotech Ossari Biotech Ltd has a P/E of 16 and a return on equity of 11.85%.
Rossari Biotech Ossari Biotech Ltd is listed on the NSE under the symbol ROSSARI and on the BSE under the scrip code 543213.
Rossari Biotech Ossari Biotech Ltd's share price is down 30.5% over one year and down 12.3% over three months. Its 52-week range is ₹375.00 to ₹638.70.
In Q2 FY27, Rossari Biotech Ossari Biotech Ltd reported revenue of ₹698 Cr and net profit of ₹39 Cr, with basic EPS of ₹7.02 (consolidated, parsed from the company's exchange filing).
Rossari Biotech Ossari Biotech Ltd reported revenue of ₹698 Cr in Q2 FY27, up 19.0% from ₹586 Cr in Q2 FY26 and up 0.1% from ₹697 Cr in Q1 FY27.
Promoters held 68.14% of Rossari Biotech Ossari Biotech Ltd's shares as of Sept 2026, against 68.17% in Sept 2025 (−0.03 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.